Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis.

Peng ZhengChunmin LiangLi RenDexiang ZhuQingyang FengWenju ChangGuodong HeLechi YeJingwen ChenQi LinTuo YiMeiling JiZhengchuan NiuMi JianYe WeiJianmin Xu

Published in: Journal of oncology (2018)

In the first-line treatment of mCRC, the predictive model integrating six new predictive mutations divided patients well, indicating a promising approach to further refine patient selection for cetuximab on the basis of RAS mutations.

Keyphrases

wild type
end stage renal disease
locally advanced
ejection fraction
newly diagnosed
metastatic colorectal cancer
peritoneal dialysis
prognostic factors
case report
squamous cell carcinoma
radiation therapy
patient reported outcomes